合并后的实体将作为Akari Therapeutics, Plc运营,预计将继续在纳斯达克资本市场上市并以AKTX的名称交易。
$海正药业(SH600267)$查看全文
Akari Therapeutics(AKTX)03-05 21:55
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-030781 Act: 34 Size: 5 MB 网页链接查看全文
Akari Therapeutics(AKTX)03-05 21:35
$Akari Therapeutics(AKTX)$ 8-K Current report, items 1.01, 7.01, and 9.01 Accession Number: 0001104659-24-030777 Act: 34 Size: 6 MB 网页链接查看全文
Akari Therapeutics(AKTX)03-30 04:25
$Akari Therapeutics(AKTX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-038661 Act: 34 Size: 9 MB 网页链接查看全文
Akari Therapeutics(AKTX)04-01 18:35
$Akari Therapeutics(AKTX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-038854 Act: 34 Size: 365 KB 网页链接查看全文
Akari Therapeutics(AKTX)03-12 05:35
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-033088 Act: 34 Size: 254 KB 网页链接查看全文
Akari Therapeutics(AKTX)03-06 06:05
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-031076 Size: 176 KB 网页链接查看全文
Akari Therapeutics(AKTX)03-12 05:25
$Akari Therapeutics(AKTX)$ 8-K Current report, items 1.01, 3.02, and 9.01 Accession Number: 0001104659-24-033087 Act: 34 Size: 535 KB 网页链接查看全文
Akari Therapeutics(AKTX)04-11 18:35
$Akari Therapeutics(AKTX)$ 8-K Current report, item 3.01 Accession Number: 0000950170-24-043519 Act: 34 Size: 264 KB 网页链接查看全文
牛唐2019-03-16 14:58
$Akari Therapeutics(AKTX)$ FDA同意coversin在HSCT-TMA适应症的关键阶段的实验设计,引发了翻倍的增长,如果后续数据好的话,未来市值有望跟相$Ra Pharmaceuticals(RARX)$ 、$奥麦罗制药(OMER)$ 相比查看全文
啃医药股的熊猫2019-03-15 11:30
【汇众医疗】3月14日上涨医药股盘点:生物制药 Akari Therapeutics 拔头筹,涨幅224.18%$$Akari Therapeutics(AKTX)$ $$Guardant Health(GH)$ 3月12日涨幅最大的三支医药股分别是:制药公司Akari Therapeutics上涨224.18%,肿瘤学公司Guardant Health上涨27.64%,康纳斯制药公司Conatus Pharmaceut...查看全文
$Akari Therapeutics(AKTX)$ 8-K Current report, item 3.01 Accession Number: 0000950170-24-043519 Act: 34 Size: 264 KB 网页链接
$Akari Therapeutics(AKTX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-038854 Act: 34 Size: 365 KB 网页链接
$Akari Therapeutics(AKTX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-038661 Act: 34 Size: 9 MB 网页链接
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-033088 Act: 34 Size: 254 KB 网页链接
$Akari Therapeutics(AKTX)$ 8-K Current report, items 1.01, 3.02, and 9.01 Accession Number: 0001104659-24-033087 Act: 34 Size: 535 KB 网页链接
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-031076 Size: 176 KB 网页链接
$Akari Therapeutics(AKTX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001104659-24-030781 Act: 34 Size: 5 MB 网页链接
$Akari Therapeutics(AKTX)$ 8-K Current report, items 1.01, 7.01, and 9.01 Accession Number: 0001104659-24-030777 Act: 34 Size: 6 MB 网页链接
$Akari Therapeutics(AKTX)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0000911420-24-000004 Act: 33 Size: 12 KB 网页链接
$Akari Therapeutics(AKTX)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-001229 Act: 34 Size: 58 KB 网页链接